Clinical Trial in a Dish
At Greenstone Biosciences, we are redefining how new medicines are developed with our Clinical Trial in a Dish platform. Traditional preclinical models often fail to capture the complexity of human biology, leaving gaps that only emerge in costly and time-intensive clinical trials. Our approach changes that by bringing clinical trial design into the laboratory—before a single patient is enrolled.
Using patient-derived induced pluripotent stem cells (iPSCs), we recreate the cellular environments of real patient populations. These models incorporate genetic diversity, demographic variables, and clinical backgrounds, allowing us to mimic how diverse groups of patients might respond to investigational therapies. This level of personalization enables developers to test hypotheses, validate endpoints, and de-risk clinical programs far earlier than ever before.
What this means for drug developers
Researchers can use Cell Village to tackle critical questions in precision medicine and drug development:
Bridging the Gap
Our Clinical Trial in a Dish platform acts as a bridge between preclinical research and human clinical studies. It delivers a level of accuracy not achievable with animal models or conventional cell culture, empowering researchers to move forward with confidence. By aligning cellular models with real-world patient variability, we accelerate timelines, reduce costs, and increase the likelihood of clinical success.
The Future of Clinical Trials Starts Here
This innovative platform supports a new paradigm in drug development—one where the patient’s biology informs every stage of the discovery and development process. By simulating clinical trials in vitro, Greenstone Biosciences is helping to bring safer, more effective therapies to patients faster.
Bring Trials into the Lab
Bridge the gap between preclinical models and human trials—start smarter with patient-informed insights.